김종민 학력
■ 세부전공 :
혈관내피세포 이질성 연구 (Research on Vascular Endothelial Cell Heterogeneity)
내피-간엽이행 기전 연구 (Mechanistic Studies of Endothelial-to-Mesenchymal Transition (EndMT))
폐동맥고혈압 치료제 개발 연구 (Development of Therapeutics for Pulmonary Arterial Hypertension (PAH))
혈관질환 치료제 개발 연구 (Development of Therapeutics for Vascular Diseases)
부인암 치료제 개발 연구 (Development of Therapeutics for Gynecologic Cancers)
■ 출신학교 :
학사 2003 단국대학교 Molecular Biology
석사 2005 단국대학교 Molecular Biology
박사 2009 단국대학교 Molecular Biology
**박사후 연수: Postdoctoral Fellow, Yale University School of Medicine, New Haven, CT. USA
■ 대표논저 :
- Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer. Cho JG, Kim SW, Yun E, Yoon S, Choi J, Yeom D, Lee A, Lee D, Jeong SJ, Chang W, Hwang WY, Kim Y, Na K, Kim KH, Suh DS, Choi KU, Park JH, Kim KI, Yoo KH, Kwon BS, Kim J*. Exp Mol Med. 2025
- Novel biomarker discovery-coupled plasma therapy with enhanced tumor penetration for non-surgical treatment of cervical cancer. Kim SW, Kang M-J, Kim YS, Hwang WY, Lee A, Le Q-V, Han I, Jung MH, Na K, Kim KS, Lee SJ, Suh DS, Kim KH, Choi KU, Choi EH, Shim G, Kim J* and Kwon BS. Journal of Controlled Release. 2025
- Ratiometric Fluorophores to ONOO– in Living Cells and Monitoring Endothelial Dysfunction. Park SY, Jo EY, Lee A, Kim NY, Kim J*, Kang C, Lee MH. Sens Actuators B Chem. 2025
- BMPR1A promotes ID2-ZEB1 interaction to suppress excessive endothelial to mesenchymal transition. Lee HW, Adachi T, Pak B, Park S, Hu X, Choi W, Kowalski PS, Chang CH, Clapham KR, Lee A, Papangeli I, Kim J, Han O, Park J, Anderson DG, Simons M, Jin SW, Chun HJ. Cardiovasc Res. 2023
- MicroRNA-dependent inhibition of WEE1 controls cancer stem- like characteristics and malignant behavior in ovarian cancer. Cho JG, Kim SW, Lee A, Jeong H-N, Yun ES, Choi J, Jeong SJ, Chang W, Oh S, Yoo KH, Lee JB, Yoon S, Lee M-S, Park JH, Jung MH, Kim S-W, Kim KH, Su DS, Choi KU, Choi J, Kim J*, Kwon BS. Mol Ther Nucleic Acids. 2022
- Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer. Lee YJ, Kim SW, Jung MH, Kim YS, Kim KS, Suh DS, Kim KH, Choi EH, Kim J*, Kwon BS. Free Radic Biol Med. 2022
- Therapeutic Engagement of the Histone Deacetylase IIA- Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension. Sofer A, Lee S, Papangeli I, Adachi T, Hwangbo C, Comhair S, DaSilva-Jardine P, Kim J, Schwarz JJ, Erzurum SC, Chun HJ. Am J Respir Crit Care Med. 2018
- MicroRNA 139-5p coordinates APLNR-CXCR4 crosstalk during vascular maturation. Papangeli I*, Kim J*, Maier I, Park S, Lee A, Kang Y, Tanaka K, Khan OF., Ju H, Kojima Y, Red-Horse K, Anderson DG, Siekmann AF, and Chun HJ. Nature Communications. 2016
- Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. Kim JD, Lee A, Choi J, Park Y, Kang H, Chang W, Lee MS, and Kim J*. Experimental & Molecular Medicine. 2015
- Restoration of Impaired Endothelial MEF2 Function Rescues Pulmonary Arterial Hypertension. Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D, Park H, McLean, DL, Ju H, Comhair SA, Erzurum SC, and Chu, HJ. Circulation. 2015
■ 재직기간 : 2013.03 ~ 현재
